Hospira Touches 52-week High - Analyst Blog
10 Julho 2013 - 1:00PM
Zacks
Shares of Hospira
Inc. (HSP) soared to a 52-week high of $39.48 towards the
end of the trading session on Jul 9, 2013 buoyed by the positive
opinion issued by the European Medicines Agency’s Committee for
Medicinal Products for Human Use (CHMP) regarding the approval of
Inflectra (infliximab).
The closing price of this company on that day was $39.44,
representing an impressive year-to-date return of 24.1%. Moreover,
Perrigo has delivered positive earnings surprises in each of the
last four quarters with an average beat of 7.14%. The long-term
expected earnings growth rate for this stock is 7.9%.
Favorable CHMP Opinion- A big Positive
Shares of Hospira have been on the upswing ever since the CHMP
recommended the approval of Inflectra for the treatment of
rheumatoid arthritis, inflammatory bowel disease and plaque
psoriasis. We note that Inflectra is the biosimilar version of
Johnson & Johnson / Merck & Co.
Inc’s (JNJ/MRK) blockbuster drug Remicade. Hospira noted
in its press release that Inflectra is the first monoclonal
antibody therapy to receive a favorable opinion from the CHMP after
review through the EMA biosimilars regulatory pathway.
Hospira, which currently markets two biosimilars in Europe, boasts
of a strong biosimilars pipeline with 11 candidates in development.
Biosimilars, which are generic versions of biologic drugs, are
expected to be a significant growth driver in the generics industry
in the coming years. The biosimilars market represents huge
commercial opportunity with a significant amount of biologic sales
slated to lose patent protection in the coming years.
A Stock Worth Considering
Hospira carries a Zacks Rank #3 (Hold). One can consider
ResMed Inc. (RMD) a good buying opportunity. This
medical stock – sporting a Zacks Rank #2 (Buy) – has performed
encouragingly over the last few quarters with potential to rise
significantly from current levels.
HOSPIRA INC (HSP): Free Stock Analysis Report
JOHNSON & JOHNS (JNJ): Free Stock Analysis Report
MERCK & CO INC (MRK): Free Stock Analysis Report
RESMED INC (RMD): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
Hospira (NYSE:HSP)
Gráfico Histórico do Ativo
De Jun 2024 até Jul 2024
Hospira (NYSE:HSP)
Gráfico Histórico do Ativo
De Jul 2023 até Jul 2024
Notícias em tempo-real sobre da New York Stock Exchange bolsa de valores: 0 artigos recentes
Mais Notícias de Hospira